Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Hricak H, Scardino PT. Prostate cancer. Cambridge University Press; UK: 2009
   Google Scholar
• Balistreri CR, Candore G, Lio D, Carruba G. Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer Gene Ther 2014;21(1):2-11
   PubMedGoogle Scholar
• Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2013;10(1):38-48
   PubMed Web of Science ®Google Scholar
• Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009;103(4):441-5
   PubMedGoogle Scholar
• Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60(2):70-98
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71
   PubMed Web of Science ®Google Scholar
• Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344(18):1373-7
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening? Ann Clin Biochem 2011;48:310-16. Available from: http://acb.rsmjournals.com/content/48/4/310.abstract
   PubMedGoogle Scholar
• Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012;4(127):127rv3
   PubMed Web of Science ®Google Scholar
• Sardana G, Diamandis EP. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomarkers Med 2012;6(5):587-96
   PubMed Web of Science ®Google Scholar
• Dijkstra S, Hamid AR, Leyten GH, Schalken JA. Personalized management in low-risk prostate cancer: the role of biomarkers. Prostate Cancer 2012;2012:327104
   PubMedGoogle Scholar
• Van Neste L, Herman JG, Otto G, et al. The epigenetic promise for prostate cancer diagnosis. Prostate 2012;72(11):1248-61
   PubMed Web of Science ®Google Scholar
• Kristiansen G. Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 2012;60(1):125-41
   PubMedGoogle Scholar
• Borre M, Bentzen SM, Nerstrom B, Overgaard J. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;159(5):1609-14
   PubMedGoogle Scholar
• Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100(6):888-93
   PubMed Web of Science ®Google Scholar
• Gunia S, Albrecht K, Koch S, et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 2008;26(3):243-50
   PubMedGoogle Scholar
• Miyake H, Muramaki M, Kurahashi T, et al. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 2010;28(2):145-51
   PubMedGoogle Scholar
• Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004;22(11):2133-40
   PubMedGoogle Scholar
• Khor LY, Bae K, Paulus R, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009;27(19):3177-84
   PubMedGoogle Scholar
• Jiang Z, Fanger GR, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 2003;34(8):792-6
   PubMedGoogle Scholar
• Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287(13):1662-70
   PubMed Web of Science ®Google Scholar
• Carswell BM, Woda BA, Wang X, et al. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy. Histopathology 2006;48(6):668-73
   PubMedGoogle Scholar
• Gologan A, Bastacky S, McHale T, et al. Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues. Am J Surg Pathol 2005;29(11):1435-41
   PubMedGoogle Scholar
• Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem 2014;47(10-11):889-96
   PubMed Web of Science ®Google Scholar
• Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8(10):826-32
   PubMed Web of Science ®Google Scholar
• Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009;22(8):1083-93
   PubMedGoogle Scholar
• Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26(31):4596-9
   PubMed Web of Science ®Google Scholar
• Rostad K, Hellwinkel OJ, Haukaas SA, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009;117(8):575-82
   PubMed Web of Science ®Google Scholar
• Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69(4):1400-6
   PubMedGoogle Scholar
• Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010;23(10):1325-33
   PubMed Web of Science ®Google Scholar
• Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13(17):5103-8
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011;3(94):94ra72
   PubMed Web of Science ®Google Scholar
• Tomlins SA. Urine PCA3 and TMPRSS2:ERG using cancer-specific markers to detect cancer. Eur Urol 2014;65(3):543-5
   PubMedGoogle Scholar
• Teixeira MR, Ribeiro FR, Eknaes M, et al. Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. Cancer 2004;101(8):1786-93
   PubMedGoogle Scholar
• Barros-Silva JD, Ribeiro FR, Rodrigues A, et al. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer 2011;50(8):662-71
   PubMedGoogle Scholar
• Ribeiro FR, Jeronimo C, Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006;12(13):3961-70
   PubMedGoogle Scholar
• DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361):955-64
   PubMedGoogle Scholar
• Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63(14):4196-203
   PubMedGoogle Scholar
• Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101(3):811-16
   PubMed Web of Science ®Google Scholar
• Kristiansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205(3):359-76
   PubMed Web of Science ®Google Scholar
• Martin SK, Vaughan TB, Atkinson T, et al. Emerging biomarkers of prostate cancer (review). Oncol Rep 2012;28(2):409-17
   PubMed Web of Science ®Google Scholar
• Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54(5):1081-8
   PubMed Web of Science ®Google Scholar
• Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6(5):255-61
   PubMed Web of Science ®Google Scholar
• Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70(1):10-16
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179(5):1804-9. discussion 9-10
   PubMed Web of Science ®Google Scholar
• Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180(5):1975-8. discussion 8-9
   PubMedGoogle Scholar
• Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110(1):43-9
   PubMed Web of Science ®Google Scholar
• Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci 2012;19:90
   PubMed Web of Science ®Google Scholar
• Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106(4):768-74
   PubMed Web of Science ®Google Scholar
• Gordanpour A, Nam RK, Sugar L, Seth A. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis 2012;15(4):314-19
   PubMedGoogle Scholar
• Kuner R, Brase JC, Sultmann H, Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013;59(1):132-7
   PubMed Web of Science ®Google Scholar
• Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126(5):1166-76
   PubMed Web of Science ®Google Scholar
• Leite KR, Tomiyama A, Reis ST, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011;185(3):1118-22
   PubMed Web of Science ®Google Scholar
• Spahn M, Kneitz S, Scholz CJ, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010;127(2):394-403
   PubMed Web of Science ®Google Scholar
• Selth LA, Townley S, Gillis JL, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012;131(3):652-61
   PubMedGoogle Scholar
• Zhang F, Liu J, Lin B, et al. Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen. Int J Mol Sci 2011;12(11):7323-34
   PubMedGoogle Scholar
• Sapre N, Selth LA. Circulating microRNAs as biomarkers of prostate cancer: the state of play. Prostate Cancer 2013;2013:539680
   PubMedGoogle Scholar
• Leader JE, Wang C, Fu M, Pestell RG. Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol 2006;72(11):1589-96
   PubMedGoogle Scholar
• Nightingale KP, O’Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 2006;16(2):125-36
   PubMedGoogle Scholar
• Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262-6
   PubMed Web of Science ®Google Scholar
• Bianco-Miotto T, Chiam K, Buchanan G, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 2010;19(10):2611-22
   PubMed Web of Science ®Google Scholar
• Ellinger J, Kahl P, von der Gathen J, et al. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest 2012;30(2):92-7
   PubMed Web of Science ®Google Scholar
• Deligezer U, Yaman F, Darendeliler E, et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta 2010;411(19-20):1452-6
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419(6907):624-9
   PubMed Web of Science ®Google Scholar
• Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280(23):22437-44
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008;27(58):7274-84
   PubMed Web of Science ®Google Scholar
• Li J, Fan QH, Fan XS, et al. [EZH2 expression in human prostate cancer and its clinicopathologic significance]. Zhonghua Nan Ke Xue 2010;16(2):123-8
   PubMedGoogle Scholar
• Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95(9):661-8
   PubMedGoogle Scholar
• Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, et al. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer 2014;21(1):51-61
   PubMed Web of Science ®Google Scholar
• Foreman KW, Brown M, Park F, et al. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One 2011;6(7):e22290
   PubMed Web of Science ®Google Scholar
• Van Aller GS, Reynoird N, Barbash O, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 2012;7(4):340-3
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6(8):731-40
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Silva FP, Tsuge M, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 2006;97(2):113-18
   PubMed Web of Science ®Google Scholar
• Brothman AR, Swanson G, Maxwell TM, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 2005;156(1):31-6
   PubMed Web of Science ®Google Scholar
• Wu T, Giovannucci E, Welge J, et al. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 2011;105(1):65-73
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93(22):1747-52
   PubMedGoogle Scholar
• Harden SV, Sanderson H, Goodman SN, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95(21):1634-7
   PubMedGoogle Scholar
• Nakayama M, Bennett CJ, Hicks JL, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003;163(3):923-33
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10(24):8472-8
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60(6):1131-5
   PubMed Web of Science ®Google Scholar
• Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7(9):2727-30
   PubMed Web of Science ®Google Scholar
• Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003;9(7):2673-7
   PubMed Web of Science ®Google Scholar
• Woodson K, O’Reilly KJ, Hanson JC, et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008;179(2):508-11. discussion 11-2
   PubMed Web of Science ®Google Scholar
• Henrique R, Jerónimo C. GSTP1 hypermethylation for prostate cancer detection. Prostate Cancer Screening. Springer; 2009. p. 279-88
   Google Scholar
• Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23(27):6569-75
   PubMed Web of Science ®Google Scholar
• Roupret M, Hupertan V, Yates DR, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13(6):1720-5
   PubMed Web of Science ®Google Scholar
• Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008;68(1):42-9
   PubMed Web of Science ®Google Scholar
• Baden J, Adams S, Astacio T, et al. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol 2011;186(5):2101-6
   PubMed Web of Science ®Google Scholar
• Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Enokida H, Shiina H, Urakami S, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005;11(18):6582-8
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11(11):4037-43
   PubMed Web of Science ®Google Scholar
• Woodson K, O’Reilly KJ, Ward DE, et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006;1(4):183-6
   PubMed Web of Science ®Google Scholar
• Weiss G, Cottrell S, Distler J, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181(4):1678-85
   PubMed Web of Science ®Google Scholar
• Henrique R, Ribeiro FR, Fonseca D, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007;13(20):6122-9
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-19
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13
   PubMed Web of Science ®Google Scholar
• Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157(2):120-34
   PubMed Web of Science ®Google Scholar